Answers are grounded in this paper and cite their sources.
Despite the challenges of drug development in rare diseases, this is an exciting time for the treatment of DS, with the promise of new efficacious and well-tolerated therapies, which may pave the way for treatment advances in other DEEs.
No takes yet. Share an insight, caveat, or question.
Strzelczyk et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: